GERN: רווח למניה בשנים עשר החודשים האחרונים geron.com

Risks for Geron Corporation (GERN) are associated with the transition from development to the global blood cancer therapy market, where high scalability promises immense revenue. The rolling annual earnings per share serves as a stability indicator, with -0.07 representing the latest level. The situation is stabilized by experienced launch managers focused on the drug's commercialization and streamlined integration with professional biopharmaceutical logistics providers to ensure uninterrupted supplies.

The positive trend in the TTM net income per share reflects the commercialization of Rytelo and the consolidation of Geron Corporation (GERN) dominance in the telomerase inhibitor segment. The current value of -0.07 is calculated as the ratio of trailing twelve-month net income to the number of shares, allowing investors to assess the real return per share and timely recognize the risk of overpaying for the asset.